CD30+ cutaneous lymphoproliferative disorders with pseudocarcinomatous hyperplasia are associated with a T-helper-17 cytokine profile and infiltrating granulocytes - 15/02/15
, Maria Estela Martinez-Escala, MD a, Janyana M.D. Deonizio, MD a, Pedram Gerami, MD a, Marshall E. Kadin, MD b, cAbstract |
Background |
The pathogenetic mechanism of CD30+ cutaneous lymphoproliferative disorders (CLPD) associated with pseudocarcinomatous hyperplasia (PCH) and granulocytic inflammation surrounding atypical CD30+ lymphocytes remains unclear.
Objective |
We sought to characterize clinical and pathological findings of a cohort of patients with PCH associated with CD30+ CLPD and to analyze the cytokine profile of the atypical lymphocytes.
Methods |
We retrospectively reviewed medical records and pathological material of CD30+ CLPD with PCH. Immunohistochemistry for T-helper (Th)17 cytokine profile was performed.
Results |
In all, 25 patients with a median age of 52 years were included. The median follow-up was 3.7 years. Histologically, an infiltrating pattern of PCH was observed in 14 cases with a neutrophilic-rich infiltrate (P = .21), and epidermal pattern in 11 cases with eosinophil-rich infiltrate (P = .03). Th17 or Th22 cytokines were detected in tumor cells in 81% cases tested. Tumor cells expressed Th17 transcription factor retinoic acid receptor (ROR)-related orphan receptor gamma-2 in 2 of 7 samples tested and 1 was positive for aryl hydrocarbon receptor.
Limitations |
This is a retrospective study of a small sample.
Conclusions |
PCH in CD30+ CLPD is associated with Th17/Th22 cytokine expression in the atypical lymphocytes. Although these lesions commonly regress spontaneously and are associated with an indolent course, some cases develop a generalized process and tumor progression.
Le texte complet de cet article est disponible en PDF.Key words : CD30+ cutaneous lymphoproliferative disorders, cytokine profile, granulocytes, pseudocarcinomatous hyperplasia, squamous cell carcinoma, T-helper-17/22
Abbreviations used : ALCL, CK17, CLPD, IL, KA, LyP, MF, PCH, SCC, Th
Plan
| Dr Kadin is supported by the Norko-Jon Family Foundation. |
|
| Conflicts of interest: None declared. |
Vol 72 - N° 3
P. 508-515 - mars 2015 Retour au numéro
Article précédent
- Histologic features of melanoma associated with CDKN2A genotype
- Michael R. Sargen, Peter A. Kanetsky, Julia Newton-Bishop, Nicholas K. Hayward, Graham J. Mann, Nelleke A. Gruis, Margaret A. Tucker, Alisa M. Goldstein, Giovanna Bianchi-Scarra, Susana Puig, David E. Elder
- Impact of a Performance Improvement CME activity on the care and treatment of patients with psoriasis
- Debra L. Gist, Reva Bhushan, Elaine Hamarstrom, Patrick Sluka, Christine M. Presta, Jennifer S. Thompson, Robert S. Kirsner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?